E
Edwin J. Whitney
Researcher at University of Texas at San Antonio
Publications - 20
Citations - 6623
Edwin J. Whitney is an academic researcher from University of Texas at San Antonio. The author has contributed to research in topics: Myocardial infarction & Cholesterol. The author has an hindex of 12, co-authored 20 publications receiving 6506 citations. Previous affiliations of Edwin J. Whitney include University of North Texas Health Science Center.
Papers
More filters
Journal ArticleDOI
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Antonio M. Gotto,Edwin J. Whitney,Evan A. Stein,Deborah R. Shapiro,Michael Clearfield,Stephen E. Weis,Jesse Y. Jou,Alexandra Langendorfer,Polly A. Beere,Douglas J. Watson,John R. Downs,John S. de Cani +11 more
TL;DR: People with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification, and on-treatment apoB, especially when combined with apoAI to form the apOB/AI ratio, may be a more accurate predictor than LDL- C of risk for first AMCE.
Journal ArticleDOI
A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
Edwin J. Whitney,Richard A. Krasuski,Bradley E. Personius,Joel E. Michalek,Ara M. Maranian,Mark W. Kolasa,Erik Monick,B. Gregory Brown,Antonio M. Gotto +8 more
TL;DR: The most suggestive evidence of benefit from an increase in HDL cholesterol level has come from trials assessing the effect on coronary stenosis, and the overwhelming treatment effect in this study was the reduction in LDL cholesterol level.
Journal ArticleDOI
Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin
John R. Downs,Michael Clearfield,H.Alfred Tyroler,Edwin J. Whitney,William Kruyer,Alexandra Langendorfer,Vladimir Zagrebelsky,Stephen E. Weis,Deborah R. Shapiro,Polly A. Beere,Antonio M. Gotto +10 more
TL;DR: Treatment with lovastatin 20 to 40 mg daily for primary prevention of coronary heart disease was well tolerated and reduced the risk of first acute coronary events without increasing the riskof either noncardiovascular mortality or cancer.
Journal ArticleDOI
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.
Michael Clearfield,John R. Downs,Stephen E. Weis,Edwin J. Whitney,William Kruyer,Deborah R. Shapiro,Evan A. Stein,Alexandra Langendorfer,Polly A. Beere,Antonio M. Gotto +9 more
TL;DR: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) is the first coronary heart disease (CHD) primary prevention trial of the cholesterol-reducing agents called "statins" to include women as discussed by the authors.